Sulphasalazine-induced leucopenia in a patient with renal dysfunction

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 3, 2003, Pages 239-242

  Teshima, Daisuke ^a   Hino, B ^a   Makino, K ^a   Yano, T ^a   Itoh, Y ^a   Joh, Y ^a   Iida, M ^a   Oishi, R ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

5 aminosalicylic acid; Leucopenia; N acetyl sulphapyridine; Serum concentration; Slow acetylator; Sulphapyridine

Indexed keywords

DRUG METABOLITE; MESALAZINE; N ACETYLSULFAPYRIDINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ACETYLATION; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG METABOLISM; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; MALE; POLYMERASE CHAIN REACTION; PROTEIN BINDING;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; KIDNEY DISEASES; LEUKOPENIA; MALE; MESALAMINE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SULFAPYRIDINE; SULFASALAZINE;

EID: 0037803498     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00484.x     Document Type: Article

References (13)

1. Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Jones FA (1965) Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet, 1, 185-188.
2. Dissanayake AS, Truelove SC (1973) A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut, 14, 923-926.
3. Das KM, Eastwood MA, McManus JPA, Sircus W (1973) Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. The New England Journal of Medicine, 289, 491-495.
4. Kita T, Sakaeda T, Adachi S, Sakai T, Aoyama N, Hatanaka H, Kasuga M, Okumura K (2001) N-Acetyltransferase 2 genotype correlates with sulfasarazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biological & Pharmaceutical Bulletin, 24, 1176-1180.
5. Khan AKA, Howes DT, Piris J, Truelove SC (1980) Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut, 21, 232-240.
6. Sharp ME, Wallance SM, Hindmarsh KW, Brown MA (1980) HPLC and GLC analysis of sulfapyridine and acetylsulfapyridine: development and selection of a suitable procedure for biological fluid analysis. Canadian Journal of Pharmaceutical Science, 15, 35-38.
7. Teshima D, Hino B, Itoh Y, Oishi R (2002) Simple and simultaneous determination of sulfapyridine and acetylsulfapyridine in human serum by column-switching high-performance liquid chromatography. Journal of Clinical Pharmacy and Therapeutics, in press.
8. Deguchi T (1992) Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. Journal of Biological Chemistry, 267, 18140-18147.
9. Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tanigawara Y (1997) Genotype of N-acetylation polymorphism and correlation with procainamide metabolism. Clinical Pharmacology and Therapeutics, 61, 509-517.
10. Das KM, Dubin R (1976) Clinical Pharmacokinetics of Sulphasalazine. Clinical Pharmacokinetics, 1, 406-425.
11. Schröder H, Campbell DES (1972) Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics, 13, 539-551.
12. Laursen LS, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K (1990) Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut, 31, 1271-1276.
13. Calder IC, Funder, CC, Green CR, Ham KN, Tange JD (1972) Nephrotoxic Lesions from 5-aminosalicylic acid. British Medical Journal, 15, 152-154.